Long-term Brain Stimulation of the Motor Ventral Thalamus (VOP/VIM) to Improve Motor Function
Launched by UNIVERSITY OF PITTSBURGH · Jul 8, 2025
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This study is looking at how long-term brain stimulation, using a treatment called Deep Brain Stimulation (DBS), can help improve movement, speech, and swallowing in people with movement disorders or brain injuries. DBS involves sending small electrical pulses to specific areas of the brain to help control symptoms like tremors or muscle stiffness. The researchers want to see how adjusting the DBS settings affects a person’s ability to move their arms, speak clearly, and swallow safely.
People who might join this study are adults between 18 and 80 years old who have movement problems and are already receiving or will receive DBS treatment. Healthy volunteers without these conditions may also participate for comparison. Participants will be asked to take part in several testing sessions where they’ll perform tasks like moving their arms, gripping objects, making facial movements, speaking, and swallowing — both with the brain stimulation turned on and off. The study excludes people with certain medical conditions like a history of seizures or fainting to keep everyone safe. This research could help improve how DBS is used to support everyday activities for people with movement difficulties.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- ALL PATIENTS:
- • Age lower than 80 to better tolerate intraoperative testing.
- • All Movement disorder patients, older than 18 and younger than 80, who will be implanted with DBS for treatment of motor symptoms.
- HEALTHY CONTROLS:
- • Subject has provided written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization, where applicable, prior to any study-related procedures.
- • Subject is ≥18 years of age and \< 80 years of age.
- • Subject is willing and able to comply with scheduled visits and study procedures.
- Exclusion Criteria:
- ALL PATIENTS:
- • Patients will be excluded from the study if there is any seizure history, to avoid the increased epileptogenic risk during stimulation testing.
- • Patients with bilateral tremors will be excluded.
- • Patients with vasovagal response history and loss of consciousness history will be excluded.
- HEALTHY CONTROLS:
- • Subject has severe behavioral or cognitive problems that preclude participation in the study, in the opinion of the investigator would impact participation in the study.
- • Participants who have any serious disease or disorder (e.g. cancer, severe cardiac or respiratory disease, neurological conditions other than stroke, etc.) or cognitive impairments that could affect their ability to participate in this study.
- • Female subjects are pregnant or breastfeeding.
About University Of Pittsburgh
The University of Pittsburgh is a leading research institution known for its commitment to advancing medical science and improving patient care through innovative clinical trials. With a robust infrastructure for research and a multidisciplinary approach, the university fosters collaboration among experts in various fields, facilitating the development of novel therapies and interventions. Its clinical trial programs emphasize ethical standards, patient safety, and the integration of cutting-edge technology, making the University of Pittsburgh a pivotal contributor to the landscape of clinical research and a trusted partner in the pursuit of health advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pittsburgh, Pennsylvania, United States
Patients applied
Trial Officials
Jorge Gonzalez-Martinez, MD, PhD
Principal Investigator
University of Pittsburgh
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported